Eli Lilly says that Zepbound is a dual receptor agonist that targets both GIP and GLP-1 receptors, unlike other incretins approved for obesity management, which target only GLP-1 receptors. And Novo Nordisk says that Wegovy has the broadest GLP-1 label, including indications for reducing risk of major adverse cardiovascular events in some patients and for treatment of a certain liver condition in some adults
In these situations, delivering nutrients directly to the bloodstream may be not merely appropriate, but essential, says Katz
Instead of idolizing clear at all costs or forcing constant self-love, acne neutrality creates space for something more realistic: acceptance and action
Researchers continue to investigate its effects on cellular regeneration, oxidative stress response, and biological aging markers
Crucially, comprehensive drug safety testing in mice indicated no significant adverse effects on myocardial, liver, or renal function markers after 30 days of treatment, suggesting a favorable safety profile [2]
